AVAC report: Getting PrEP rollout right this time

AVAC released its new report, Getting PrEP Rollout Right This Time: Lessons from the Field, that examines key insights from the rollout of oral PrEP and early introduction of injectable cabotegravir (CAB) and the dapivirine vaginal ring (DVR) to inform a faster, smarter and more equitable introduction of future HIV prevention tools, including long-acting injectable PrEP, such as lenacapavir.

AVAC conducted in-depth interviews with policymakers, program implementers, and advocates in seven countries (Brazil, Kenya, Nigeria, South Africa, Vietnam, Zambia, and Zimbabwe) to understand how policy, procurement, service delivery, and community engagement have shaped the uptake of oral PrEP and the introduction on DVR and CAB. The findings offer critical insights into what must change, what must be sustained, and what must be built to ensure new HIV prevention options are rolled out with speed, scale and equity.

This analysis comes at a pivotal moment as the US Administration is actively working to dismantle HIV research and demolish the architecture of global health. The entire HIV response from basic research and clinical development to policy, programs, and global access to life-saving treatment and prevention is now under attack. All this as the field reaches a moment of historic promise in HIV prevention, with initial regulatory approval of LEN for PrEP from the US Food and Drug Administration expected by next Thursday, June 19. This report lays out what’s needed at this critical time to get HIV prevention into the hands of those that need it most.

Access the report here.